Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.95 USD | +0.79% | -7.76% | -25.00% |
May. 28 | Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia | CI |
May. 23 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 2.85B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.64% | 21.96B | |
-9.30% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients